Certara toxicology experts to support NIH’s BPN and HEAL drug development programs for nervous system disorders including addiction and chronic pain
Princeton, N.J., January 10, 2023 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announces that the U.S. National Institutes of Health (NIH) has awarded a contract to Certara for ongoing toxicology support for the agency’s Blueprint Neurotherapeutics Network (BPN) and the Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative’s Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain Program. BPN helps academic labs and small biotech companies develop new treatments for neurological disorder patients with unmet medical needs, while HEAL spurs development of new treatments for improving prevention and treatment for opioid misuse and addiction and enhancing pain management.
Both BPN and HEAL leverage external consulting expertise in critical elements of pharmaceutical development, including non-clinical safety assessment of drug candidates, which is the core expertise of Certara’s toxicology division. Since 2014, BPN has been supported by toxicology and non-clinical experts from Integrated Nonclinical Development Solutions (INDS), Inc. Certara acquired INDS in January 2022 and that business is now part of the organization’s Integrated Drug Development group.
“An award of this contract to Certara by the NIH allows continuity of the support that Certara toxicologists provide to BPN and extends our expertise to support the critical, unmet patient needs targeted by the HEAL Initiative,” said William F. Feehery, PhD., CEO of Certara. “We are honored by the confidence expressed by the NIH in our capabilities and mindful of the trust placed in our teams to provide key support for programs designed to improve the lives of individuals living with pain or addiction.”
“Safety and toxicity issues must be fully evaluated in drug development. Mitigating any concerns is critical to determining a drug development program’s success or failure,” said Patrick Smith, PharmD, President of Certara’s Integrated Drug Development group. “NIH’s contract allows Certara to bring toxicology expertise to these important initiatives so sponsors can easily access our services without direct expense.”
In addition to providing support for BPN and HEAL, the NIH contract covers provision of toxicology consulting services to the National Institute of Neurological Disorders and Stroke (NINDS) and other NIH neuroscience-focused drug discovery and development programs. This project is funded with Federal funds from the National Institutes of Health, Department of Health and Human Services, under Contract No. 75N95022P00647.
To learn more, please contact firstname.lastname@example.org.
Certara accelerates medicines using proprietary biosimulation software, technology, and teams of pharmaceutical development experts with broad and complementary expertise to transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries.